RxDoctor Payments DataLook up a doctor →

William Lanting, MD

Allergy · Fort Collins, CONPI 1205866837

Payments from drug & device makers

$35,900in general payments, 2019–2025

Across 707 payments — averaging $50.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$12K
  • Sanofi$6K
  • AstraZeneca$4K
  • Shire North American Group Inc$4K
  • Regeneron Healthcare Solutions, Inc.$3K
  • GSK$1K
  • plus $7K from 28 others

What the payments were for

  • Consulting fees$5,59616%
  • Speaking & faculty fees$13,58938%
  • Travel & lodging$1,0963%
  • Food & beverage$15,47143%
  • Education$1480%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy providers in Coloradoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$37,551
Medicare patients
95
Services billed
2,387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HyqviaIgg/Hyaluronidase,recombinant26$256,418
Dupixent SyringeDupilumab56$209,481
Dupixent PenDupilumab28$120,790
Advair HfaFluticasone Propion/Salmeterol189$95,320
XolairOmalizumab11$35,466
DuleraMometasone/Formoterol83$35,330
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$30,943
Mycophenolate Mofetil13$16,457
Breo ElliptaFluticasone/Vilanterol31$14,810
Spiriva RespimatTiotropium Bromide23$11,955
Fluticasone-Salmeterol HfaFluticasone Propion/Salmeterol18$8,203
SymbicortBudesonide/Formoterol Fumarate32$8,086
Mometasone Furoate73$6,250
Levocetirizine Dihydrochloride372$4,280
Epinephrine13$4,004

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Hyqvia$1,142$256,41826 claims
GSKTrelegy Ellipta, Breo Ellipta$1,257$45,75363 claims
MerckDulera$37$35,33083 claims
Boehringer IngelheimSpiriva Respimat$186$11,95523 claims
AstraZenecaSymbicort$3,856$8,08632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Coloradoon file to place this against a meaningful peer group, so we don't.

Other allergy in Fort Collins

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →